News of the index components OMX NORDIC 40

Index

OMXN40

SE0001809476

Real-time Nasdaq Stockholm 10:31:21 2024-06-11 am EDT			5-day change	1st Jan Change
2,909 ^PTS	-0.71%		+1.57%	+14.70%

Jun. 05	Nordic Shares Moved Upward Wednesday; Crayon Group Topped Leaders	DJ
May. 31	Nordic Shares Moved Upward Friday; NEL Topped Leaders	DJ

News of the index components

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Danske Bank A/S : S&P RatingsDirect DanicaPensionLivsforsikringsaktieselskab May 30 2024 DANSKE	Jun. 03	PU
Marimekko and Stora Enso collaborate to create new, dynamic and renewable gift packaging STERV	Jun. 03	AQ
New number of shares and votes in Telefonaktiebolaget LM Ericsson ERIC B	Jun. 03	AQ
Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study GMAB	Jun. 03	MT
Novo Nordisk A/S - share repurchase programme NOVO B	Jun. 03	GL
Transcript : Genmab A/S - Special Call GMAB	Jun. 03
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) GMAB	Jun. 03	BU
Transactions in Connection with Share Buy-back Program GMAB	Jun. 03	GL
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) GMAB	Jun. 03	GL
Genmab A/S Announces Data from the Phase 2 Innovatv 207 Trial, Investigating Tisotumab Vedotin GMAB	Jun. 03	CI
Genmab A S and BioNTech SE Announces Initial Data from the Ongoing Phase 2 Trial GMAB	Jun. 03	CI
Carlsberg A/S : Brooklyn Brewery and Spike Lee collaborate to create global campaign CARL B	Jun. 03	PU
Nokia Enters Partnership for Transportation, Logistics Technology Research in India NOKIA	Jun. 03	MT
Nokia Bags Infrastructure Upgrade Contract from Telehouse America NOKIA	Jun. 03	MT
JPMorgan European G&I raises dividend after outperforming benchmark NOVO B	Jun. 03	AN
Carlsberg A/S share buy-back programme CARL B	Jun. 03	AQ
Ericsson Concludes Anti-corruption Compliance Monitoring With US Government ERIC B	Jun. 03	MT
AP Moller Maersk : Tax information MAERSK B	Jun. 03	PU
Ericsson Reports Conclusion of DOJ Monitorship ERIC B	Jun. 03	MT
Ericsson: end of anti-corruption surveillance in the USA ERIC B	Jun. 03	CF
Carlsberg A/S : appoints two new members of Executive Committee CARL B	Jun. 03	PU
Nokia and Gati Shakti Vishwavidyalaya sign MoU for research collaboration on transportation and logistics NOKIA	Jun. 03	AQ
Danske Bank share buy-back programme: Transactions in week 22 DANSKE	Jun. 03	GL
Nokia and Gati Shakti Vishwavidyalaya Sign MOU for Research Collaboration on Transportation and Logistics NOKIA	Jun. 03	CI
Ericsson says U.S. anti-corruption compliance monitoring has ended ERIC B	Jun. 03	RE
Nokia selected by Telehouse America to upgrade NYIIX peering exchange infrastructure in the US NOKIA	Jun. 03	AQ
Telehouse America Selects Nokia to Upgrade NYIIX Peering Exchange Infrastructure in the US NOKIA	Jun. 03	CI
Ericsson Concludes U.S. Plea Deal Following Bribery Allegations ERIC B	Jun. 03	DJ
Fortum Oyj : Battery Recycling Oy and Marubeni Corporation sign Memorandum of Understanding to address the demand for recycled raw materials FORTUM	Jun. 03	PU
Ericsson announces conclusion of Monitorship ERIC B	Jun. 03	AQ
Genmab Announces Initial Data from Phase 2 Cancer Treatment Trial GMAB	Jun. 03	MT
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma GMAB	Jun. 02	AQ
Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma GMAB	Jun. 02	CI
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma GMAB	Jun. 02	GL
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma GMAB	Jun. 02	BU
ESSITY : EPS cut (2023: -9.6%, 2024: -1.3%) ESSITY B	Jun. 01
Genmab A/S : Investigational Acasunlimab (DuoBody® PD L1x4 1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non small Cell Lung Cancer (mNSCLC) GMAB	Jun. 01	PU
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC) GMAB	Jun. 01	BU
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC) GMAB	Jun. 01	GL
Nokia Corporation: Repurchase of own shares on 31.05.2024 NOKIA	May. 31	GL